Deadly meningitis outbreak tied to more drugs, FDA says
A second steroid manufactured by New England Compounding Center has been linked to another potential meningitis infection, U.S. regulators said. The second steroid, triamcinolone acetonide, is used to treat skin conditions that result in itching, redness, dryness, and inflammation, according to the National Institutes of Health. The patients received the medication through an epidural injection. Transplant patients have also experienced fungal infections after being given a drug from the pharmacy meant to induce cardiac muscle paralysis during open-heart surgery, the Food and Drug Administration said.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- 3 Traits Personality Assessments Can't Reveal
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CHS Hacked, 4.5M Patient Records Compromised
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- CFO Exchange: Healthcare Leaders Share 5 Innovative Ideas
- Large Employers Trimming Healthcare Spending
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital